ARTICLE | Company News
MedImmune in Vitaxin deal with Targesome
February 22, 2001 8:00 AM UTC
The companies will combine MEDI's Vitaxin, a humanized antibody angiogenesis inhibitor, with Targesome's nanoparticle technology in efforts to develop a targeted nanoparticle that delivers either ther...